Placebo Causes Adverse Reaction With Industry, Raises Regulatory Concerns
This article was originally published in The Tan Sheet
Executive Summary
An inert sugar pill marketed as a placebo for ailing children will likely attract regulatory interest from the Federal Trade Commission as well as FDA, according to industry experts